Macrogenics Inc is a pioneering biopharmaceutical firm focused on crafting innovative antibody-based treatments for cancer. With a flagship product, MARGENZA, designed for advanced HER2-positive breast cancer, the company stands at the forefront of cancer therapy. Beyond MARGENZA, Macrogenics boasts a diverse pipeline targeting solid tumors and hematologic malignancies through cutting-edge technologies like antibody drug conjugates and bispecific antibodies. Their research also extends into immune checkpoint inhibitors, offering new hope in the fight against cancer. Based in Rockville, Maryland, Macrogenics collaborates with global partners to advance its mission of transforming cancer treatment.